Abbott Laboratories (NYSE: ABT) has a price-to-earnings ratio of 34.70x that is above its average ratio. Additionally, the 36-month beta value for ABT is 0.72. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 7 rating it as “overweight,” 7 rating it as “hold,” and 0 rating it as “sell.”
The public float for ABT is 1.73B and currently, short sellers hold a 0.81% ratio of that float. The average trading volume of ABT on October 28, 2024 was 5.45M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ABT) stock’s latest price update
The stock price of Abbott Laboratories (NYSE: ABT) has dropped by -1.99 compared to previous close of 116.54. Despite this, the company has seen a fall of -4.33% in its stock price over the last five trading days. fool.com reported 2024-10-26 that These healthcare stocks have fantastic dividend track records.
ABT’s Market Performance
Abbott Laboratories (ABT) has seen a -4.33% fall in stock performance for the week, with a 1.32% gain in the past month and a 9.02% surge in the past quarter. The volatility ratio for the week is 1.61%, and the volatility levels for the past 30 days are at 1.53% for ABT. The simple moving average for the past 20 days is -1.15% for ABT’s stock, with a 3.33% simple moving average for the past 200 days.
Analysts’ Opinion of ABT
Many brokerage firms have already submitted their reports for ABT stocks, with Oppenheimer repeating the rating for ABT by listing it as a “Outperform.” The predicted price for ABT in the upcoming period, according to Oppenheimer is $130 based on the research report published on October 08, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see ABT reach a price target of $131. The rating they have provided for ABT stocks is “Overweight” according to the report published on September 19th, 2024.
ABT Trading at -0.32% from the 50-Day Moving Average
After a stumble in the market that brought ABT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -6.10% of loss for the given period.
Volatility was left at 1.53%, however, over the last 30 days, the volatility rate increased by 1.61%, as shares surge +1.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.96% upper at present.
During the last 5 trading sessions, ABT fell by -4.33%, which changed the moving average for the period of 200-days by -0.16% in comparison to the 20-day moving average, which settled at $115.55. In addition, Abbott Laboratories saw 3.77% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ABT starting from ALLEN HUBERT L, who sale 157,421 shares at the price of $117.04 back on Oct 21 ’24. After this action, ALLEN HUBERT L now owns 184,806 shares of Abbott Laboratories, valued at $18,424,298 using the latest closing price.
ALLEN HUBERT L, the Officer of Abbott Laboratories, proposed sale 157,421 shares at $118.89 during a trade that took place back on Oct 21 ’24, which means that ALLEN HUBERT L is holding shares at $18,715,783 based on the most recent closing price.
Stock Fundamentals for ABT
Current profitability levels for the company are sitting at:
- 0.17 for the present operating margin
- 0.55 for the gross margin
The net margin for Abbott Laboratories stands at 0.14. Equity return is now at value 14.47, with 7.56 for asset returns.
When we switch over and look at the enterprise to sales, we see a ratio of 4.82. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.68.
Conclusion
In conclusion, Abbott Laboratories (ABT) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
